Systemic retinoids in chemoprevention of non-melanoma skin cancer

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1363-1374

  Lens, Marko ^a   Medenica, Ljiljana ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Chemoprevention; Non melanoma skin cancer; Retinoids

Indexed keywords

ADAPALENE; AROTINOID; BEXAROTENE; ETRETIN; ISOTRETINOIN; PSORALEN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; RETINOL; TAZAROTENE; TETRACYCLINE; DERMATOLOGICAL AGENT;

ABDOMINAL PAIN; ACNE VULGARIS; AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTHRALGIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BLURRED VISION; BONE DISEASE; BONE MALFORMATION; BRAIN PSEUDOTUMOR; CANCER PATIENT; CARDIOVASCULAR MALFORMATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHEILITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONGENITAL DISORDER; CONJUNCTIVITIS; CORNEA OPACITY; CORNEA ULCER; CRANIOFACIAL MALFORMATION; DARK ADAPTATION; DEPRESSION; DESQUAMATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EAR DISEASE; EYE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPERLIPIDEMIA; HYPEROSTOSIS; INCIDENCE; INTRACRANIAL HYPERTENSION; IRRITABILITY; KERATITIS; LETHARGY; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOSAL DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; NONMELANOMA SKIN CANCER; PALMOPLANTAR KERATODERMA; PAPILLEDEMA; PATIENT SELECTION; PHOTOPHOBIA; PLEIOTROPY; PREGNANCY; PSORIASIS; PSYCHOSIS; PUVA; RETINA MALFORMATION; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SKIN CARCINOGENESIS; SKIN FRAGILITY; SPONDYLOARTHROPATHY; SQUAMOUS CELL CARCINOMA; SUICIDE; SYSTEMIC THERAPY; TERATOGENICITY; THYMUS DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASCULITIS; VISION; VISUAL DISORDER; XERODERMA PIGMENTOSUM; XEROPHTHALMIA; CHEMOPROPHYLAXIS; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; SKIN TUMOR;

ACITRETIN; ADMINISTRATION, ORAL; CHEMOPREVENTION; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOTRETINOIN; PATIENT SELECTION; RETINOIDS; SKIN NEOPLASMS;

EID: 45549088781     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1363     Document Type: Review

References (97)

1. Trakatelli M, Ulrich C, Del Marmol V, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007;156(Suppl 3):1-7
2. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002;41(3):269-85
3. Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol 2007;57(3):484-501 4 Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63(1-3):8-18
4. Mackie RM. Long-term health risk to the skin of ultraviolet radiation. Prog Biophys Mol Biol 2006;92(1):92-6
5. Almahroos M, Kurban AK. Ultraviolet carcinogenesis in nonmelanoma skin cancer part II: review and update an epidemiologic correlations. Skinmed 2004;3(3):132-9
6. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702
7. Scherschun L, Lim HW. Photoprotection by sunscreens. Am J Clin Dermatol 2001;2(3):131-4
8. Wolverton SE. Retinoids. In: Wolverton SE, editor, Systemic drugs for skin diseases. Philadelphia, PA: WB Saunders; 1991. p. 187-218
9. Bollag W. From vitamin A to retinoids: chemical and pharmacological aspects. In: Orfanos CE, Braun-Falco EM, Farber EM, et al., editors, Retinoids: advances in basic research and therapy. Berlin: Springer-Verlag; 1981. p. 5-11
10. Nguyen EH, Wolverton SE. Systemic retinoids. In: Wolverton SE, Wilkin JK, editors, Systemic drugs for skin diseases. Philadelphia: WB Saunders; 2000. p. 269-310
11. Chambon P. The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 2005;19:1418-28
12. Germain P, Chambon P, Eichele G, et al. International union of pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006;58:712-25
13. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54
14. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 2007;75(9):853-70
15. Giguere V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocrinol Rev 1994;15:61-79
16. Mollard R, Viville S, Ward SJ, et al. Tissue-specific expression of retinoic acid receptor isoform transcripts in the mouse embryo. Mech Dev 2000;94:223-32
17. Fisher GJ, Talwar HS, Xiao JH. Immunological identification and functional quantification of retinoic and retinoid X receptor protein in human skin. J Biol Chem 1994;269:20629-35
18. Davidovici BB, Tüzün Y, Wolf R. Retinoid receptors. Dermatol Clin 2007;25(4):525-30
19. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004;328:1-16
20. Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR α. Nature 1992;355:359-61
21. Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Ann Rev Pharmacol Toxicol 2006;46:451-80
22. Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocrinol Metabol Disord 2001;1(2):153-64
23. Xiao JH, Durand B, Chambon P, Voorhees JJ. Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers to confer ligand-dependent activation of hRAR beta 2/RARE (DR5). J Biol Chem 1995;270(7):3001-11
24. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002;43:1773-808
25. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50
26. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41
27. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44
28. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465-74
29. Woychik NA, Hampsey M. The RNA polymerase II machinery: structure illuminates function. Cell 2002;108:453-63
30. Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 2001;20:3047-54
31. Digiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992;54:63-128
32. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 2000;5(5):361-8
33. Cheepala SB, Syed Z, Trutschl M, et al. Retinoids and skin: microarrays shed new light on chemopreventive action of all-trans retinoic acid. Mol Carcinogen 2007;46(8):634-9
34. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Natl Rev Cancer 2001;1:181-93
35. Mraas P, Rendl M, Mildner M, et al. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res 2004;64(18):6542-8
36. Lotan R. Retinoic receptors and retinoid-regulated differentiation markers as intermediate endpoints in chemoprevention. Proc Am Asaoc Cancer Res 1994;35:684-5
37. Levine N. Role of retinoids in skin cancer treatment and prevention. J Am Acad Dermatol 1998;39(2 Pt 3):S62-6
38. Spinella MJ, Freemantle SJ, Sekula D, et al. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999;274:22013-8
39. Langenfeld J, Kiyokawa H, Sekula D, et al. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 1997;94:12070-4
40. Eckhart L, Declercq W, Ban J, et al. Terminal differentiation of human keratinocytes and stratum corneum formation is associated with caspase-14 activation. J Invest Dermatol 2000;115:1148-51
41. Rendl M, Ban J, Mrass P, et al. Caspase-14 expression by epidermal keratinocytes is regulated by retinoids in a differentiation-associated manner. J Invest Dermatol 2002;119:1150-5
42. Fisher GJ, Talwar HS, Lin J, et al. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 1998;101:1432-40
43. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372:107-11
44. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Natl Rev Cancer 2004;4:23-35
45. Campbell RM, Digiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther 2006;19(5):306-14
46. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269-73
47. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006;32(4):562-8
48. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(Suppl 61):1 50 Berg D, Otley CC. Skin cancer in organ transplant recipients. Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17
49. Hartevelt MM, Bouwes Bavinck JN, Kootte AMM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49:506-9
50. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 2005;19:726-34
51. Euvrard S, Kanitakis J, Claudy J. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
52. Kraemer KH, Lee MM, Scott J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241-50
53. Epstein JRE. Basal cell nevus syndrome. In: Freedberg IM, Eisen AZ, Wolf K, et al., editors, Fitzpatrick's dermatology in general medicine. 6th edition. New York: McGraw-Hill; 2003. p. 755-60
54. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer: PUVA follow-up study. J Natl Cancer Inst 1998;90:1278-84
55. Orfanos C, Zouboulis C, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53(3):358-88
56. Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 1998;39(2 Pt 3):S8-12
57. Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998;39(2 Pt 3):S25-33
58. Pearce D, Klinger S, Ziel K, et al. Low-dose acitretin is associated with fewer adverse events than high dose acitretin in the treatment of psoriasis. Arch Dermatol 2006:142:1000-4
59. Neuhaus IM, Tope WD. Practical retinoid chemoprophylaxis in solid organ transplant recipients. Dermatol Ther 2005;18(1):28-33
60. Harwood CA, Leedham-Green M, Leigh IM, Proby MC. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005;141(4):456-64
61. Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997;6:957-61
62. Kraemer KH, Digiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7
63. Goldberg LH, Hsu SH, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol 1989;21:144-5
64. Bavinck JN, Tieben LM, Van Der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind placebo controlled study. J Clin Oncol 1995;13:1933-8
65. De Sevaux RG, Smit JV, De Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomised trial comparing two doses of acitretin. J Am Acad Dermatol 2003;49(3):407-12
66. Schaller M, Korting HC, Wolff H, et al. Multiple keratoacanthomas and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Dermatol Venereol 1996;76:40-2
67. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of nan-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269-73
68. Mckenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60
69. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005;152:518-23
70. Nijsten TEC, Robert S, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644-50
71. Desai A, Kartono F, Del Rosso JQ. Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin 2007;25:185-93
72. Digiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45(5):S176-82
73. Shalita AR. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 1987;175:151-7
74. Gold JA, Shupack JL, Nemec MA. Ocular side effects of the retinoids. Int J Dermatol 1989;28:218-25
75. Fraunfelder FT, Labraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100:534-7
76. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001;132:299-305
77. Gross EG, Helfgott MA. Retinoids and the eye. Dermatol Clin 1992;10(3):521-31
78. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006;142(8):1016-22
79. Zech la, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983;119(12):987-93
80. Bershad S, Rubinstein A, Paterniti JR, at al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313(16):981-5
81. Van De Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19(5):252-63
82. Koo J, Nguyen Q, Gamba C. Advances in psoriasis therapy. Adv Dermatol 1997;12:47-72
83. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003;49(2):171-82
84. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 1992;27:S29-33
85. Mader R. Current therapeutic options in the management of diffuse idiopathic skeletal hyperostosis. Expert Opin Pharmacother 2005;6(8):1313-8
86. Belanger TA, Rowe DE. Diffuse idiopathic skeletal hyperostosis: musculoskeletal manifestations. J Am Acad Orthop Surg 2001;9(4):258-67
87. Nesher G, Zuckner J. Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum 1995;24(4):291-6
88. Kaplan G, Haettich B. Rheumatological symptoms due to retinoids. Baillieres Clin Rheumatol 1991;5(1):77-97
89. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001;45(Suppl):S150-7
90. Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005;55(511):134-8
91. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988;3(4):273-88
92. Sekula-Gibbs U, Uptmore D, Ottilar L. Retinoids. J Am Acad Dermatol 2004;50(3):405-15
93. Food and Drug Administration: iPLEDGE update. 2006. Available from: http://www.fda.gov/cder/drug/infopage/accutane/iPLEDGEupdate200603.htm [Last accessed 25 November 2007]
94. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;3(11):e483
95. Grønhøj Larsen F, Steinkjer B, Jakobsen P, et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000;143(6):1164-9
96. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994;189(2):109-16
97. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993;100:623-7